Literature DB >> 3358890

Absorption of 5-aminosalicylic acid from colon and rectum.

S Bondesen1, J B Schou, V Pedersen, Z Rafiolsadat, S H Hansen, E F Hvidberg.   

Abstract

In order to clarify the characteristics of absorption of 5-aminosalicylic acid (5-ASA) from the colon, a neutral solution was instilled into the right part of the colon and the rectum, respectively, in six volunteers. A laxative (bisacodyl) and liquid meals were given prior to each instillation. No significant difference could be demonstrated between the two parts of the large bowel, but the absorption was considerably restricted compared with previous results obtained from the jejunum. The results confirm in a direct manner earlier observations on 5-ASA released from sulphasalazine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358890      PMCID: PMC1386484          DOI: 10.1111/j.1365-2125.1988.tb03301.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

2.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

3.  Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high-performance liquid chromatography on dynamically modified silica.

Authors:  S H Hansen
Journal:  J Chromatogr       Date:  1981-12-11

4.  5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern.

Authors:  S Bondesen; O H Nielsen; O Jacobsen; S N Rasmussen; S H Hansen; S Halskov; V Binder; E F Hvidberg
Journal:  Scand J Gastroenterol       Date:  1984-07       Impact factor: 2.423

5.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

Authors:  O Haagen Nielsen; S Bondesen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

6.  Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.

Authors:  R A van Hogezand; P A van Hees; B Zwanenburg; J M van Rossum; J H van Tongeren
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

7.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

8.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

9.  Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.

Authors:  A K Azad Khan; S C Truelove
Journal:  Gut       Date:  1980-08       Impact factor: 23.059

10.  Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.

Authors:  S Bondesen; O H Nielsen; J B Schou; P H Jensen; L B Lassen; V Binder; P A Krasilnikoff; P Danø; S H Hansen; S N Rasmussen
Journal:  Scand J Gastroenterol       Date:  1986-08       Impact factor: 2.423

  10 in total
  10 in total

Review 1.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

2.  Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults.

Authors:  Amalia Diakidou; Maria Vertzoni; Konstantinos Goumas; Erik Söderlind; Bertil Abrahamsson; Jennifer Dressman; Christos Reppas
Journal:  Pharm Res       Date:  2009-07-02       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes.

Authors:  M Pirmohamed; M D Coleman; F Hussain; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

5.  Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.

Authors:  E C Van Os; B J Zins; W J Sandborn; D C Mays; W J Tremaine; D W Mahoney; A R Zinsmeister; J J Lipsky
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 6.  Clinical pharmacokinetics of slow release mesalazine.

Authors:  M De Vos
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 7.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

8.  Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation.

Authors:  S Bondesen; J Hegnhøj; F Larsen; S H Hansen; C P Hansen; S N Rasmussen
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

9.  Oroileal transit of slow release 5-aminosalicylic acid.

Authors:  H Goebell; U Klotz; B Nehlsen; P Layer
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

10.  Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity.

Authors:  Aurelio Romero-Castro; Mara Gutiérrez-Sánchez; José Correa-Basurto; Martha Cecilia Rosales Hernández; Itzia Irene Padilla Martínez; Jessica Elena Mendieta-Wejebe
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.